Henry Schein Still Gives Me A Reason To Smile After This Nice Move Higher

Summary Henry Schein remains a dominant global provider of dental and medical practitioner supplies, with recent share price outperformance versus the S&P 500. HSIC delivered strong Q2 results: revenue up 6.7% to $3.46B, net income and cash flow both meaningfully improved, and all business segments showed growth. Management raised 2026 guidance, now expecting 4.5–5.5% revenue growth and adjusted EPS of $5.29–$5.39, reflecting ongoing operational momentum. Despite recent gains, HSIC trades at a relative discount to peers and warrants a soft ‘buy’ rating for its quality, growth, and market leadership. Looking for a helping hand in the market? Members of Crude Value Insights get exclusive ideas and guidance to navigate any climate. Learn More » OR Images/DigitalVision via Getty Images Back in June of this year, I decided to take a fresh look at Henry Schein ( HSIC ) , a rather interesting company that is a major player globally in the provision of dental This article was written by Daniel Jones 37.9K Followers Follow Daniel is an avid and active professional investor. He runs Crude Value Insights, a value-oriented newsletter aimed at analyzing the cash flows and assessing the value of companies in the oil and gas space. His primary focus is on finding businesses that are trading at a significant discount to their intrinsic value by employing a combination of Benjamin Graham's investment philosophy and a contrarian approach to the market and the securities therein. Learn more. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.